Literature DB >> 27716265

Erratum to: Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria.

Bernhard Rintelen1,2, Jochen Zwerina3, Manfred Herold4, Franz Singer5, Johann Hitzelhammer6, Wolfgang Halder7, Gabriela Eichbauer-Sturm8, Rudolf Puchner9, Miriam Stetter10, Burkhard F Leeb11,12,13.   

Abstract

Entities:  

Year:  2016        PMID: 27716265      PMCID: PMC5048649          DOI: 10.1186/s12891-016-1270-x

Source DB:  PubMed          Journal:  BMC Musculoskelet Disord        ISSN: 1471-2474            Impact factor:   2.362


× No keyword cloud information.

Erratum

After publication of the original article [1], it came to the authors’ attention that in the third paragraph of the ‘Discussion’ section, the value of DAS28 in NEW included patients is indicated wrongly, although correctly cited in Table 2. The correct form of the erroneous sentence is as follows: “NEW patients´ median disease activity according to the DAS28 before starting bDMARDs is in the lower range in BIOREG compared to other European bDMARD registries (4.46 compared to 4.2–6.6), while median HAQ-DI scores are in a comparable range (1.0 vs 0.8–1.9).” To correct the original sentence, “(4.46 compared to 4.2–6.6)” should be updated to “(4.13 compared to 4.2–6.6)”, and “in the lower range” should replace “somewhat lower”.
  1 in total

1.  Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria.

Authors:  Bernhard Rintelen; Jochen Zwerina; Manfred Herold; Franz Singer; Johann Hitzelhammer; Wolfgang Halder; Gabriela Eichbauer-Sturm; Rudolf Puchner; Miriam Stetter; Burkhard F Leeb
Journal:  BMC Musculoskelet Disord       Date:  2016-08-22       Impact factor: 2.362

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.